GenoMed Can Explain Link Between West Nile, Diabetes/Hypertension
This observation has now been made in California, New York and Texas. The link appears to be over-activity of the angiotensin I-converting enzyme, abbreviated "ACE."
In 2002, GenoMed published a series of four papers showing that over- activity of ACE led to diabetes and hypertension, as well as to complications like heart and kidney disease. Using the right dose of the right ACE inhibitor, it was possible to reverse diabetic or hypertensive kidney disease for the first time.
In 2004, GenoMed published that a similar approach was successful in treating over 80% of patients with West Nile virus encephalitis. GenoMed's treatment success rate for WNV encephalitis is currently 86% (19 of 22 patients improved rapidly).
In 2003, GenoMed filed patent applications claiming that ACE inhibitors and angiotensin II blockers may be a near-universal viral antidote, because previously healthy people who get sick from nearly all viral diseases suffer from a "cytokine storm" initiated by too much angiotensin II. Angiotensin II is made by ACE. GenoMed's viral antidote was included in the Project BioShield II Act of 2005, since it would be an ideal public health response to viral bioterrorism.
Said Dr. Moskowitz, GenoMed's CEO and Chief Medical Officer, "GenoMed goes from the molecular mechanism of disease directly to practical treatments that are safe and useful at the population level. It's very gratifying to get separate epidemiologic confirmation that we've discovered something huge."
GenoMed's general viral antidote is being offered for any viral epidemic around the globe. In the U.S., GenoMed's approach has worked well against West Nile virus encephalitis since 2003. Anyone on earth can download the protocol for avian influenza or West Nile virus for free from GenoMed's website, http://www.genomed.com , at any time of day or night. GenoMed simply requests an email address to make clinical follow-up possible.
Safe Harbor Statement
This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:
Backing, Christopher. "GenoMed Can Explain Link Between West Nile, Diabetes/Hypertension." Medical News Today. MediLexicon, Intl., 27 Jun. 2006. Web.
30 Mar. 2017. <http://www.medicalnewstoday.com/releases/45971.php>
Backing, C. (2006, June 27). "GenoMed Can Explain Link Between West Nile, Diabetes/Hypertension." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.